These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 27563003)
1. [Antibodies against modified low-density lipoproteins and their complexes in blood of patients with various manifestations of atherosclerosis]. Belik IV; Ivantsova AA; Mamedova ZE; Denisenko AD Biomed Khim; 2016 May; 62(4):471-5. PubMed ID: 27563003 [TBL] [Abstract][Full Text] [Related]
3. Immunization with malondialdehyde-modified low-density lipoprotein (LDL) reduces atherosclerosis in LDL receptor-deficient mice challenged with Porphyromonas gingivalis. Turunen SP; Kummu O; Wang C; Harila K; Mattila R; Sahlman M; Pussinen PJ; Hörkkö S Innate Immun; 2015 May; 21(4):370-85. PubMed ID: 25134521 [TBL] [Abstract][Full Text] [Related]
4. Characteristics of low density lipoprotein isolated from circulating immune complexes. Tertov VV; Sobenin IA; Orekhov AN; Jaakkola O; Solakivi T; Nikkari T Atherosclerosis; 1996 May; 122(2):191-9. PubMed ID: 8769682 [TBL] [Abstract][Full Text] [Related]
5. Relationship of Autoantibodies to MDA-LDL and ApoB-Immune Complexes to Sex, Ethnicity, Subclinical Atherosclerosis, and Cardiovascular Events. Prasad A; Clopton P; Ayers C; Khera A; de Lemos JA; Witztum JL; Tsimikas S Arterioscler Thromb Vasc Biol; 2017 Jun; 37(6):1213-1221. PubMed ID: 28473443 [TBL] [Abstract][Full Text] [Related]
6. Autoantibodies to malondialdehyde-modified low-density lipoprotein in patients with angiographically confirmed coronary artery disease. McDowell A; Young IS; Wisdom GB J Pharm Pharmacol; 2002 Dec; 54(12):1651-7. PubMed ID: 12542895 [TBL] [Abstract][Full Text] [Related]
7. Increased levels of autoantibodies against copper-oxidized low density lipoprotein, malondialdehyde-modified low density lipoprotein and cardiolipin in patients with rheumatoid arthritis. Cvetkovic JT; Wållberg-Jonsson S; Ahmed E; Rantapää-Dahlqvist S; Lefvert AK Rheumatology (Oxford); 2002 Sep; 41(9):988-95. PubMed ID: 12209031 [TBL] [Abstract][Full Text] [Related]
8. The IgM response to modified LDL in experimental atherosclerosis: hypochlorite-modified LDL IgM antibodies versus classical natural T15 IgM antibodies. van Leeuwen M; Damoiseaux J; Duijvestijn A; Heeringa P; Gijbels M; de Winther M; Tervaert JW Ann N Y Acad Sci; 2009 Sep; 1173():274-9. PubMed ID: 19758162 [TBL] [Abstract][Full Text] [Related]
9. Activation of the immune system and inflammatory activity in relation to markers of atherothrombotic disease and atherosclerosis in rheumatoid arthritis. Wållberg-Jonsson S; Cvetkovic JT; Sundqvist KG; Lefvert AK; Rantapää-Dahlqvist S J Rheumatol; 2002 May; 29(5):875-82. PubMed ID: 12022343 [TBL] [Abstract][Full Text] [Related]
12. Circulating malondialdehyde-modified low-density lipoprotein levels are associated with the presence of thin-cap fibroatheromas determined by optical coherence tomography in coronary artery disease. Matsuo Y; Kubo T; Okumoto Y; Ishibashi K; Komukai K; Tanimoto T; Ino Y; Kitabata H; Hirata K; Imanishi T; Akagi H; Akasaka T Eur Heart J Cardiovasc Imaging; 2013 Jan; 14(1):43-50. PubMed ID: 22573905 [TBL] [Abstract][Full Text] [Related]
13. The level of malondialdehyde-modified LDL and LDL immune complexes in patients with rheumatoid arthritis. Wang J; Hu B; Meng Y; Zhang C; Li K; Hui C Clin Biochem; 2009 Sep; 42(13-14):1352-7. PubMed ID: 19501077 [TBL] [Abstract][Full Text] [Related]
14. Circulating malondialdehyde-modified LDL and atherogenic lipoprotein profiles measured by nuclear magnetic resonance spectroscopy in patients with coronary artery disease. Miyazaki T; Shimada K; Sato O; Kotani K; Kume A; Sumiyoshi K; Sato Y; Ohmura H; Watanabe Y; Mokuno H; Daida H Atherosclerosis; 2005 Mar; 179(1):139-45. PubMed ID: 15721020 [TBL] [Abstract][Full Text] [Related]
15. IgM anti-malondialdehyde low density lipoprotein antibody levels indicate coronary heart disease and necrotic core characteristics in the Nordic Diltiazem (NORDIL) study and the Integrated Imaging and Biomarker Study 3 (IBIS-3). van den Berg VJ; Haskard DO; Fedorowski A; Hartley A; Kardys I; Caga-Anan M; Akkerhuis KM; Oemrawsingh RM; van Geuns RJ; de Jaegere P; van Mieghem N; Regar E; Ligthart JMR; Umans VAWM; Serruys PW; Melander O; Boersma E; Khamis RY EBioMedicine; 2018 Oct; 36():63-72. PubMed ID: 30131305 [TBL] [Abstract][Full Text] [Related]
16. Gold nanoparticle-antibody conjugates for specific extraction and subsequent analysis by liquid chromatography-tandem mass spectrometry of malondialdehyde-modified low density lipoprotein as biomarker for cardiovascular risk. Haller E; Lindner W; Lämmerhofer M Anal Chim Acta; 2015 Feb; 857():53-63. PubMed ID: 25604820 [TBL] [Abstract][Full Text] [Related]
17. Circulating antibodies recognising oxidatively-modified low-density lipoproteins in patients with IgA nephropathy, membranous glomerulonephritis and focal glomerulosclerosis. Fornasieri A; Perugini C; Seccia M; Napodano P; D'Amico G; Bellomo G J Nephrol; 2002; 15(4):349-57. PubMed ID: 12243363 [TBL] [Abstract][Full Text] [Related]
18. Oxidation of low-density lipoprotein cholesterol following administration of poloxamer 407 to mice results from an indirect effect. Johnston TP; Zhou X J Cardiovasc Pharmacol; 2007 Apr; 49(4):246-52. PubMed ID: 17438410 [TBL] [Abstract][Full Text] [Related]
19. Reduced IgM levels and elevated IgG levels against oxidized low-density lipoproteins in HIV-1 infection. Yilmaz A; Jennbacken K; Fogelstrand L BMC Infect Dis; 2014 Mar; 14():143. PubMed ID: 24636004 [TBL] [Abstract][Full Text] [Related]
20. Autoantibodies against low-density lipoprotein and atherogenic potential of blood. Kacharava AG; Tertov VV; Orekhov AN Ann Med; 1993 Dec; 25(6):551-5. PubMed ID: 8292305 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]